Literature DB >> 33735759

Frequency of oculomotor disorders in adolescents 11 to 17 years of age with concussion, 4 to 12 weeks post injury.

Mitchell Scheiman1, Matthew F Grady2, Erin Jenewein3, Ruth Shoge3, Olivia E Podolak4, David H Howell5, Christina L Master2.   

Abstract

The purpose of the study was to determine the frequency of vision diagnoses after concussion in adolescents and evaluate the sensitivity and specificity of physician-administered screening for detecting convergence and accommodative disorders post-concussion. We enrolled participants 11 to 17 years old, assessed 4 to 12 weeks following a diagnosed concussion. During the initial concussion examination, a sports medicine physician measured the near point of convergence (NPC), monocular accommodative amplitude (AA), and symptoms using the Convergence Insufficiency Symptom Survey (CISS). A comprehensive oculomotor evaluation was performed by an optometrist. One hundred and thirteen adolescents were enrolled, with a mean age of 15.2 years. Seventy-nine of the 113 (70%) participants had at least one oculomotor diagnosis after concussion, with the most common problems being vergence disorders (60%) and accommodative disorders (57%). The most common vergence disorder was convergence insufficiency (35%). Among accommodative disorders, the most common problem was accommodative insufficiency (35%). In all, 47% of the participants had more than one oculomotor diagnosis following concussion. The sensitivity of physician screening using measures of NPC, AA, and CISS for detecting convergence and accommodative insufficiency was 63%, 43%, 48%, respectively. The results of this study provide additional evidence that vision problems are common in adolescents with persistent concussion symptoms in the sub-acute phase 4 to 12 weeks post-concussion, and current physician screening methods using the NPC, AA, or the CISS underperform. Thus, it is prudent that adolescents with post-concussion symptoms lasting more than 4 weeks post injury receive a comprehensive oculomotor examination.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  Accommodative insufficiency; Concussion; Concussion-related vision disorders; Convergence insufficiency; Saccadic dysfunction

Mesh:

Year:  2021        PMID: 33735759     DOI: 10.1016/j.visres.2020.09.011

Source DB:  PubMed          Journal:  Vision Res        ISSN: 0042-6989            Impact factor:   1.886


  5 in total

1.  Eye Tracking Metrics Differences among Uninjured Adolescents and Those with Acute or Persistent Post-Concussion Symptoms.

Authors:  Divya Jain; Kristy B Arbogast; Catherine C McDonald; Olivia E Podolak; Susan S Margulies; Kristina B Metzger; David R Howell; Mitchell M Scheiman; Christina L Master
Journal:  Optom Vis Sci       Date:  2022-07-14       Impact factor: 2.106

2.  Trajectories of Visual and Vestibular Markers of Youth Concussion.

Authors:  Kristy B Arbogast; Riddhi P Ghosh; Daniel J Corwin; Catherine C McDonald; Fairuz N Mohammed; Susan S Margulies; Ian Barnett; Christina L Master
Journal:  J Neurotrauma       Date:  2022-10       Impact factor: 4.869

3.  OculoMotor Assessment Tool: Children Compared with Adults.

Authors:  Rachel Eichler; Gila Mivtachi; Dina Hershkovitz-Azoulay; Mitchell Scheiman; Hadas Ben-Eli
Journal:  Clin Optom (Auckl)       Date:  2022-05-27

4.  Disparity vergence differences between typically occurring and concussion-related convergence insufficiency pediatric patients.

Authors:  Tara L Alvarez; Chang Yaramothu; Mitchell Scheiman; Arlene Goodman; Susan A Cotter; Kristine Huang; Angela M Chen; Matthew Grady; Anne E Mozel; Olivia E Podolak; Chris G Koutures; Christina L Master
Journal:  Vision Res       Date:  2021-04-23       Impact factor: 1.984

5.  Validation of the Symptom Questionnaire for Visual Dysfunctions (SQVD): A Questionnaire to Evaluate Symptoms of any Type of Visual Dysfunctions.

Authors:  Pilar Cacho-Martínez; Mario Cantó-Cerdán; Francisco Lara-Lacárcel; Ángel García-Muñoz
Journal:  Transl Vis Sci Technol       Date:  2022-02-01       Impact factor: 3.283

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.